China Animal Welfare Law Under Review While 36,000 Dogs Culled
BEIJING, June 16 /PRNewswire-USNewswire/ -- Today the Chinese state media announced that the dog cull in Hanzhong city, Shaanxi Province has reached a death toll of 36,000. Claiming rabies outbreak, the city has sent out dog-beating squads to kill any animal spotted on the street, stray or owned. ...
Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
LAUSANNE, Switzerland, October 21 /PRNewswire/ -- Debiopharm Group
(Debiopharm), a global biopharmaceutical development specialist that
focuses on serious medical conditions and particularly oncology, announced
today that the first healthy elderly subjects have been randomised in a
clinical bi...
Karolinska Institutet to Test Vical's Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL ) today announced a research collaboration with the Karolinska
Institutet (KI), a leading European medical university, and the Swedish
Institute for Infectious Disease Control (SMI), a governmental expert
agency, to...
Karolinska Institute to Test Vical's Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL ) today announced a research collaboration with the Karolinska
Institute, a leading European medical university, and the Swedish Institute
for Infectious Disease Control (SMI), a governmental expert agency, to
evalu...
MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
MONMOUTH JUNCTION, N.J., Aug. 5 /PRNewswire/ -- MicroDose Technologies
Inc. (MicroDose) today announced that the first clinical milestone in its
collaboration with Merck & Co., Inc., through a Merck affiliate, has been
achieved, triggering the first payment
under the global license agreement
f...
Michael J. Fox Foundation Funds $1.1 Million for Cutting-Edge Approaches to Parkinson's Disease Under Rapid Response Innovation Awards 2008
$2 million in total funding expected by year's end
NEW YORK, July 29 /PRNewswire-USNewswire/ -- Gene silencing techniques
and induced pluripotent stem cell technology are among the cutting-edge
approaches to Parkinson's drug development funded through The Michael J.
Fox Foundation's Rapid Re...
Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL ) today announced that the company has successfully completed
first-year milestones
under a three-year, $6.0 million grant awarded in
2007, and is advancing with the development of a DNA vaccine manufacturing
proces...
Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration
SEATTLE, June 19 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc.
(Nasdaq: TRBN ) today announced that Wyeth Pharmaceuticals, a division of
Wyeth (NYSE: WYE ), has exercised its option
under the terms of its
collaboration agreement with Trubion to extend the research period for an
addi...
Lupus Under the Spotlight: U.S. Congress Shows Support for Women's Health Issues
NEW YORK, May 12 /PRNewswire-USNewswire/ -- The Alliance for Lupus
Research (ALR) commends the Senate on its passage of a resolution
supporting the goals and ideals of National Women's Health Week that begins
annually on Mother's Day. The resolution, introduced by Senators Russ
Feingold (D-WI)...
Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc.
(Nasdaq: ARNA ) announced today that Taisho Pharmaceutical Co., Ltd.
initiated a Phase 1 clinical trial of a drug candidate
under a GPCR-focused
partnership with Arena to develop compounds to treat psychiatric disorders.
T...
Aida Announces New Anti-Cancer Drug Under Development
SANTA MONICA, Calif., April 18 /PRNewswire-FirstCall/ -- Aida
Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) (hereinafter referred to
as "Aida") today announced that it is developing a potential cancer drug
that seeks to trigger cell death in certain types of cancer.
Vasostatin-Apo2L, a pre-...
Michael J. Fox Foundation Commits up to $10 Million for Pre-Clinical Drug Development Under Therapeutics Development Initiative
- 2008 program includes special funding track for academic researchers
-
NEW YORK, April 1, 2008 /PRNewswire-USNewswire/ -- The Michael J. Fox
Foundation for Parkinson's Research seeks applications from industry and
academic researchers for its $10-million 2008 Therapeutics Development
Ini...
Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses
ARLINGTON, Va., Jan. 25 /PRNewswire-USNewswire/ -- A report released
today by The Cornucopia Institute presents research indicating that new
additives placed in infant formula are seriously endangering the health of
some formula-fed newborns and toddlers.
The report, 'Replacing Mother--Imi...
Five Clinical Studies to Receive $2.5 Million Under Foundation's 2007 Clinical Discovery Program
NEW YORK, Dec. 4 /PRNewswire-USNewswire/ -- The Michael J. Fox
Foundation for Parkinson's Research today announced approximately $2.5
million in total funding for five clinical research studies
under its 2007
Clinical Discovery Program. In keeping with the Foundation's focus on
accelerating sc...
Rx for Africa, Inc. Now Trading Under New Symbol (RXAF.PK)
NEW YORK, Oct. 31 /PRNewswire-FirstCall/ -- Rx for Africa, Inc. (Other
OTC: RXAF.PK), announced today that effective immediately, its stock will
now trade
under the symbol RXAF.PK and that the name "Diamond
Entertainment" and its symbol (DMON.PK) will no longer be used as part of
the company's...
DURECT Provides an Update to the Memryte Program Under Development
by Voyager Pharmaceutical Corp
CUPERTINO, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- DURECT
Corporation announced today that Voyager Pharmaceutical has
provided its shareholders with an update on its truncated Phase 3
clinical trial for Memryte, an investigational drug for the
treatment of Alzheimer's disease. Voyager has i...
Tiny Cup Attached to Eye Improves Drug Delivery For Retinal Diseases
...do Carvalho, M.D., Ph.D. and the company 3T Ophthalmics which is developing the drug delivery system.
The episcleral drug reservoir is inserted
under the thin, filmy conjunctiva, or covering of the eyeball, to the sclera -- the fibrous, protective outer layer of the eye. The tiny cup administers the...
Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
... and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed
under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended Decemb...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...ctuates based on the nature and timing of payments
under agreements with the Company's partners, including ...ted)
Research and development
revenue
under collaborative
agreements ...nue:
Research and development
revenue
under collaborative
agreements ...
NewCardio Announces Master Services Agreement With Dedicated Phase I
...d QTc studies, has signed a Master Services Agreement (MSA) with NewCardio.
under terms of this agreement, Dedicated Phase I will receive a license to use Ne...cardiovascular disease (CVD), as well as cardiac safety assessment of drugs
under development. NewCardio's three-dimensional ECG platform is designed to redu...
Labopharm files New Drug Submission with Health Canada for novel antidepressant
...ajor European markets and Australia. The Company's second product, a novel formulation of trazodone for the treatment of major depressive disorder, is
under regulatory review in the U.S. by the FDA. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. ...
NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
... particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus
under current good-manufacturing practices (cGMP) at its new vaccine manufacturin...lity to construct and produce GMP-quality influenza vaccine within 12 weeks
under real pandemic conditions is an important and successful test of our VLP tec...
DNA Helps Reunite Children With Their Families
... FORT WORTH, Texas, Aug. 4 /PRNewswire-USNewswire/ -- Of the 600,000-800,000 people trafficked across international borders each year, 50 percent are
under 17. It is estimated that by 2010, human trafficking will be the No. 1 crime worldwide.
Arthur Eisenberg, Ph.D., professor and chairman of th...
Debiopharm Group and Mercury Therapeutics, Inc. Sign an Exclusive License Agreement for the Development and Commercialisation of Debio 0930
...er fasting blood glucose levels and improve glucose disposal
following a glucose challenge, two key goals in the management of type 2
diabetes.
under the terms of the agreement, Debiopharm shall pay Mercury for
continued research and development support, predefined advanced milestone
payments during...
Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
... from its Far East partners in the ordinary course
under their collaborative agreements.
"Our Chines...ght to all clinical data generated in the Far East
under the agreements entered into with their Far East pa...ter China Region and to JCOM, Ltd for South Korea.
under these agreements both of these partners will be co...
Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor
...affect the accuracy of forward-looking statements
included in this press release or which may otherwise affect Tower's and
Jazz's business is included
under the heading "Risk Factors" in Tower's most
recent filings on Forms 20-F, F-3, F-4 and 6-K, as were filed with the
Securities and Exchange Commission (...
Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
...submission of the New
Drug Application (NDA) for velaglucerase alfa allowed
under the Fast Track
process.
"We are very pleased with the progress of th...e Company's website:
http://www.shire.com .
"SAFE HARBOR" STATEMENT
under THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995
Statements incl...
John Legend and Gap Join (PRODUCT)RED(TM) to Help Eliminate AIDS in Africa with Exclusive (RED)ZONE Seating at Madison Square Garden
... Inc.
Gap Inc. is a leading global specialty retailer offering clothing, accessories and personal care products for men, women, children and babies
under the Gap, Banana Republic, Old Navy, Piperlime and Athleta brand names. Fiscal 2008 sales were $14.5 billion. Gap Inc. operates more than 3,100 stores ...
Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
...ications
richard.smith@pharmasset.com
Office: +1 (609) 613-4181
Forward-Looking Statements
Pharmasset "Safe Harbor" Statement
under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forwa...
FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia
...
In Europe, a Marketing Authorization Application (MAA) for asenapine,
under the brand name SYCREST(R), is currently
under review by the European Medicines Agency (EMEA) for the treatment of schizop...
Diabetes Gene Raises Odds of Lower Birth Weight
... was implicated in both lower birth weight and type 2 diabetes, and the current study, using a large sample size, reinforced that association.
under the fetal insulin hypothesis, a slight underproduction of insulin, an important fetal growth factor, during the prenatal period may cause a baby to be...
FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents
...er strong results.
For further information on Shire, please visit the Company's website:
http://www.shire.com .
"SAFE HARBOR" STATEMENT
under THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995
Statements included herein that are not historical facts are
forward-looking statements. S...
Wyeth Reports Publication of Phase 3 Data for Bazedoxifene/Conjugated Estrogens, an Investigational Compound Being Studied for the Treatment of Menopausal Symptoms
...ange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion
under the caption "Item 1A, Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Ex...
First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center
...ed X-ray source rather than radioactive isotopes.
The Riverview center initiated treatments on three patients with non-melanoma skin cancers
under the direction of James S. Welsh, M.S., M.D., the center's radiation oncologist and a clinical professor in the Department of Human Oncology and Medica...
Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
... not for patients with type 1 "juvenile" diabetes or diabetic ketoacidosis. ACTOS has not been studied in children and is not recommended for children
under the age of 18. ACTOS may be taken alone or with a sulfonylurea, metformin, or insulin.
I mportant Safety Information About ACTOS
ACTO...
Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
...estigational compounds for the treatment of several types of cancer and reflects Lilly's current beliefs. However, as with any pharmaceutical product
under development, there are substantial risks and uncertainties in the process of development and regulatory review. There is no guarantee that the product...
Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
... TWISTHALER will not relieve sudden asthma symptoms and is not for children
under the age of 4.
ASMANEX TWISTHALER is available in two dose strengt...ow blood pressure (such as dizziness or faintness). If you or your child is
under stress, such as with surgery, after surgery, or trauma, you may need steroi...
July 2009 Mayo Clinic Women's HealthSource Highlights Food Storage Safety, Energy Therapies and Vitamins and Minerals
...y greater than 1,000 milligrams (mg) per day, can cause liver damage. High doses of niacin should be considered a prescribed medication and taken only
under a doctor's supervision.
Vitamin C: Studies have shown that eating food high in vitamin C can lower rates of cancer and heart disease. It's...
July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair
...ed. The July issue of Mayo Clinic Health Letter looks at new technologies
under study to repair heart valve disorders without open heart surgery.
...his approach may not be as effective as other approaches. A larger study is
under way.
For now, open heart surgery will continue to be the mainstay...
Awardees for the 2009 Young Investigator Grant for Probiotics Research Announced
...the advancement of probiotics study in the United States.
DANONE is the world's leading producer of yogurt products. These products are sold
under the DANNON and DANONE brand names. Since its foundation, DANONE has built its business on product offerings which combine health benefits and taste. D...